City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders.
The post City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver appeared first on MedCity News.
